Every Form 4 that DFP HLDGS LTD (DFPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DFPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DFPH filings page.
Oncology Institute, Inc. (TOI) reported an equity award to its Chief Financial Officer, who is an officer and reporting person of the company. On 11/17/2025, the CFO acquired 195 shares of common stock as restricted stock units (RSUs) that were fully vested upon grant, with no cash price shown for the shares. After this transaction, the officer beneficially owned 235,369 shares of TOI common stock in direct ownership. The RSUs were net of shares withheld to cover tax obligations.
Oncology Institute (TOI) Chief Executive Officer Daniel Virnich reported an insider equity award. The Form 4 shows 6,211 shares of common stock acquired at $0.00 on 11/12/2025, reflecting RSUs that were fully vested upon grant and settled net of withholding taxes. Following this transaction, he beneficially owned 1,793,520 shares, held directly.
Oncology Institute, Inc. (TOI) insider activity: A Form 4 reports that the company’s Chief Medical Officer acquired common stock via restricted stock units (RSUs) that were fully vested upon grant on 11/12/2025.
The filing lists two RSU-related acquisitions at a price of $0.00 per share: 306 shares and 1,202 shares, reported as net of withholding tax obligations. Following these transactions, the reporting person beneficially owned 235,844 shares.